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Inflammation and chronic kidney disease predict
cardiovascular events. Here we evaluated markers of
inflammation including fibrinogen, albumin and white blood
cell count in individuals with and without stages 3–4 chronic
kidney disease to assess inflammation as a risk factor for
adverse events, the synergy between inflammation and
chronic kidney disease, and the prognostic ability of these
inflammatory markers relative to that of C-reactive protein.
Using Atherosclerosis Risk in Communities and
Cardiovascular Health Study data, inflammation was
defined by worst quartile of at least 2 of these 3 markers.
In Cox regression models, inflammation was assessed as a
risk factor for a composite of cardiac events, stroke and
mortality as well as components of this composite. Among
20413 patients, inflammation was identified in 3594 and
chronic kidney disease in 1649. In multivariable analyses,
both inflammation and chronic kidney disease predicted all
outcomes, but their interaction was non-significant. In 5597
patients with C-reactive protein levels, inflammation and
elevated C-reactive protein had similar hazard ratios. When
focusing only on individuals with the worst quartile of
white cell count and albumin, results remained consistent.
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Individuals with chronic kidney disease (CKD) are at
increased risk of cardiovascular disease (CVD) and
all-cause mortality, and it is hypothesized that both traditional
and non-traditional CVD risk factors may account for
this increased risk.1–3 One non-traditional risk factor is
inflammation.4,5
Inflammation is a systemic condition, mediated by
the interplay of multiple factors, including cytokines,
complement, and white blood cells (WBCs). For example,
C-reactive protein (CRP), a non-specific acute-phase reactant
marking inflammation, requires interleukin-6 and either
interleukin-1 or tumor necrosis factor-a for upregulation,
whereas a second acute-phase reactant, fibrinogen, requires
interleukin-6 for upregulation, but is inhibited by inter-
leukin-1 and tumor necrosis factor-a.6 Elevated fibrinogen is
generally a later, but more sustained, phenomenon in the
setting of inflammation than elevated CRP.6 Other acute-
phase responses, leukocytosis and hypoalbuminemia, occur
early following an inflammatory stimuli, and changes may be
sustained in chronic inflammatory states.6
Individuals with CKD have several potential inflammatory
stimuli, including ischemia, infection, and the uremic milieu.
An imbalance in pro- and antioxidant agents in CKD,
perhaps mediated by impaired proinflammatory cytokine
clearance, may contribute.7 In the general population,
inflammation is an established risk factor for CVD, with
leukocytosis and CRP both independently associated with
cardiovascular outcomes.4,8,9 Several studies have shown
an association between inflammatory markers and outcomes
in CKD populations.10,11 Although it is hypothesized that
inflammation may be the unifying concept between kidney
disease and the enhanced CVD risk in CKD,12 the interaction
between inflammation and CKD has not been compared in a
general population study.
In this study, we examined the effects of inflammation
on cardiovascular and mortality outcomes, using established
inflammatory markers (fibrinogen, albumin, WBC count) in
individuals with and without chronic kidney disease to assess
(1) inflammation as a risk factor for adverse events; (2)
synergy between inflammation and CKD to evaluate potential
differences in the importance of inflammation among
individuals with and without CKD; and (3) importance of
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these markers relative to CRP in individuals with and without
CKD.
RESULTS
Among 20 413 individuals (mean age 59.3±10.2 years) 1649
(8.1%) had CKD, 4732 (23.2%) were African American, 3471
(17.0%) had prior CVD, and 1970 (9.7%) were diabetic.
Mean WBC count was 6.0±2.0 cells mm3, mean serum
albumin was 41±3 g l1 (4.1±0.3 g per 100 ml), and mean
fibrinogen was 9.1±1.9 mmol l1 (309±66 mg/dl). There
were 3594 individuals (17.6% individuals) with two of three,
and 740 individuals (3.4%) with all three characteristics in
the worst quartile. Individuals with inflammation were older,
more often African American and male, and more likely to
have hypertension, diabetes, and CKD (Table 1). There were
2483 (12.4%) cardiac events and 4958 (24.8%) composite
events over 105±30 months of follow-up in individuals with
complete data (Table 2). Events were significantly more
common in those with inflammation (Po0.001).
In univariate and multivariable analyses, elevated WBC
count, reduced serum albumin, and increased fibrinogen
were all associated with adverse outcomes (Table 2). The
composite variable that defined inflammation by being in the
worst quartile of two of these three inflammatory markers
was also associated with all adverse outcomes in univariate
and multivariable analyses (Table 2). This composite term for
inflammation was associated with lower Akaike information
criterion values and higher hazard ratios (HRs) than any of
the individual components of the composite when examining
the same number of individuals (data not shown). The HRs
(95% confidence intervals) associated with CKD in multi-
variable models that also adjusted for inflammation were 1.12
(1.10, 1.26), 1.24 (1.06, 1.46), 1.50 (1.36, 1.65), and 1.22
(1.13, 1.33) for cardiac, stroke, mortality, and composite
outcomes, respectively. The proportional hazards assumption
was met for multivariable models.
Inflammation and reduced kidney function
There were 1570 (95.2%). individuals with CKD with
complete data for multivariable analyses (the majority
without complete data were missing electrocardiograms to
determine left-ventricular hypertrophy). Although inflam-
mation was more common in individuals with CKD (12.9
versus 7.1%; Po0.001), it was a statistically significant risk
factor for only mortality and composite events in this
subpopulation (Table 3). The addition of inflammation to
models did not affect overall predictive ability despite
statistical significance (data not shown). Reclassifying WBC
count using non-race-specific values did not change results
(data not shown). Interaction terms defining the relationship
between inflammation and CKD were non-significant with
b-coefficients of negative sign, implying that, while CKD
and inflammation both are associated with increased risk
of adverse events, they are primarily additive rather than
synergistic and may even incorporate some similar risks
(Table 4).
CRP and other inflammation markers
We examined CRP and the inflammation composite in the
5597 individuals from Cardiovascular Health Study (CHS)
with CRP and other inflammatory marker data at baseline.
As 23% of the CHS population was defined as having
inflammation by the composite inflammation variable, we
defined elevated CRP by the highest 23% of CRP values (CRP
Table 1 | Baseline characteristics and clinical events for the
cohort stratified by the presence of absence of inflammation
No inflammation
n=16 819
(82.4%)
Inflammation
n=3594 (17.6%)
Total
n=20413
Demographics
Age 59.0±10.1 61.6±10.9 59.4±10.3
Female 54.7 60.0 55.6
African American 21.2 32.7 23.2
High school graduate 76.7 67.2 75.0
ARIC 74.3 63.8 72.5
Medical history
Diabetes 8.0 17.5 9.7
Hypertension 43.9 59.4 46.6
Cardiovascular disease 15.4 24.4 17.0
Current smoker 18.8 38.4 22.3
Current alcohol use 56.6 45.6 54.6
Clinical findings
Systolic blood pressure 124.6±20.4 129.4±22.6 125.5±20.9
Diastolic blood pressure 73.0±11.2 72.5±12.2 72.9±11.4w
Left-ventricular
hypertrophy
2.5 4.5 2.8
Body mass index 27.0±4.7 28.8±6.0 27.3±5.0
Laboratory results
Serum creatinine 78±20 80±27 79±21
Estimated GFR 1.48±0.35 1.48±0.42 1.48±0.36*
Reduced eGFR 7.1 12.1 8.1
Hemoglobin 139±14 138±16 139±14
Total cholesterol 5.54±0.39 5.46±1.12 5.53±1.07
HDL cholesterol 1.37±0.44 1.26±0.39 1.35±0.43
Non-HDL cholesterol 4.17±1.10 4.20±1.16 4.18±1.11z
Inflammatory markers
Albumin 41±2 39±3 41±3
Fibrinogen 293±53 384±70 309±66
WBC count 5.8±1.7 8.0±2.6 6.2±2.0
CRP 2.6±4.0 6.9±10.2 3.6±10.3
ARIC, Atherosclerosis Risk in Communities; CRP, C-reactive protein; eGFR, estimated
filtration rate; GFR, glomerular filtration rate; HDL, high-density lipoprotein; WBC,
white blood cell.
Inflammation was defined by having two of the following three characteristics:
upper quartile of fibrinogen (X344mg per 100ml), upper quartile of WBC count
(X6.7 in African Americans, X7.3 in Whites), and lower quartile of albumin (o3.9 g
per 100ml).
P-valueo0.001 for differences between individuals with and without inflammation,
except *P40.20, zPo0.20, and wPo0.05.
All events reflect 10-year incidence. Cardiac events include myocardial infarction,
fatal coronary disease, and coronary revascularization.
All measurements are mean±s.d. for continuous measures or percent for
categorical variables. Blood pressure is in mmHg. Body mass index is in kgm2.
Serum creatinine and fibrinogen measurements are in mmol l1. Cholesterol
measures are in mmol l1. GFR is in ml s1 1.73m2. Hemoglobin and albumin are
in g l1. WBC count is in 109 cells l3. CRP is in mg l1.
To convert to mg per 100ml, divide creatinine by 88.4, fibrinogen by 0.0294, and
cholesterol measures by 0.02586. To convert to g per 100ml, divide albumin and
hemoglobin by 10. To convert to ml s1 1.73m2, multiply eGFR by 60.
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X3.6 mg l1). There was significant collinearity between
these 2 variables (j-coefficient¼ 0.27; Po0.001), even
though only 44% of individuals with ‘inflammation’ had
high CRP. The inflammation composite and elevated CRP
were statistically significant risk factors for adverse outcomes
and were of similar magnitude in all models (Table 5).
However, in the CKD subgroup, neither inflammation
composite nor elevated CRP were statistically significant risk
factors for adverse outcomes (P40.3 for all except P¼ 0.08
for CRP with composite outcomes); this may be a power
issue as the interaction term for CKD with inflammatory
markers was non-significant in all models. In sensitivity
analyses, we used first used CRP X3 mg l1 and then CRP
X10 mg l1 to define individuals with inflammation. We
then varied the criteria for cut-off points for the inflamma-
tion composite term, with similar numbers seen for elevated
CRP and the inflammation composite with stratification
of inflammatory markers at the worst tertile (for CRP
X3 mg l1) and worst 15% (for CRP X10 mg l1) of two of
three inflammatory markers. Results for elevated CRP and
Table 2 | Unadjusted and adjusted risk of adverse events associated with inflammation as well as individual markers of
inflammation
Events: n (%) Cardiac 2483 (12.4%) Stroke 1083 (5.4%) Death 3059 (15.3%) Composite 4958 (24.8%)
Inflammation components
WBC Univariate 1.15 (1.13, 1.17) 1.14 (1.11, 1.17) 1.15 (1.13, 1.16) 1.14 (1.13, 1.16)
Albumin Univariate 0.90 (0.87, 0.94) 0.77 (0.73, 0.82) 0.74 (0.71, 0.76) 0.82 (0.80, 0.85)
Fibrinogen Univariate 1.33 (1.28, 1.37) 1.38 (1.31, 1.44) 1.41 (1.37, 1.45) 1.36 (1.33, 1.39)
WBC Multivariable 1.06 (1.03, 1.09) 1.07 (1.03, 1.11)a 1.07 (1.05, 1.09) 1.07 (1.05, 1.08)
Albumin Multivariable 0.90 (0.87, 0.94) 0.87 (0.82, 0.92) 0.85 (0.82, 0.88) 0.89 (0.86, 0.91)
Fibrinogen Multivariable 1.12 (1.08, 1.17) 1.10 (1.04, 1.16)b 1.16 (1.13, 1.20) 1.14 (1.11, 1.17)
Inflammation composite
Composite Univariate 1.95 (1.79, 2.12) 2.24 (1.97, 2.54) 2.19 (2.03, 2.37) 2.00 (1.89, 2.13)
Composite Multivariable 1.35 (1.23, 1.49) 1.46 (1.27, 1.67) 1.42 (1.31, 1.54) 1.37 (1.28, 1.46)
WBC, white blood cell.
Per s.d. change: 2 109 cells l3 (2000 cellsmm3) rise in WBC count; 2.7 g/l (0.27 g/dl) rise in serum albumin; and 1.9 mmol/l (66mg/dl) rise in fibrinogen.
Inflammation composite refers to having two of the following three characteristics: upper quartile of fibrinogen (X10.1 mmol/l (344mg per 100ml)), upper quartile of WBC
count (X6.7 in African Americans, X7.3 in Whites), and lower quartile of albumin (o39 g l1 (o3.9 g per 200ml)).
Multivariable models are adjusted for presence or absence of kidney disease, anemia, age, sex, race, prior cardiovascular disease, history of diabetes, history of hypertension,
LVH, smoking, alcohol use, high school graduation status, body mass index, systolic blood pressure, non-HDL cholesterol, and study of origin. Number of events and
multivariable hazards reflect individuals with complete baseline data (n=19 986).
All P-values o0.0001 except the following:
aP=0.0003 and
bP=0.002.
Table 3 | Inflammation and adverse events in individuals with CKD
Events: n (%) Cardiac 392 (25.0%) Stroke 209 (13.3%) Death 671 (42.7%) Composite 841 (53.6%)
Univariate 1.58 (1.29, 1.94) 1.51 (1.14, 1.99) 1.76 (1.51, 2.05) 1.66 (1.45, 1.91)
Multivariable 1.14 (0.91, 1.43) 1.14 (0.84, 1.55) 1.24 (1.05, 1.47) 1.19 (1.02, 1.39)
CKD, chronic kidney disease.
Multivariable analyses and number of events based on the 1570 individuals with eGFR o1ml s1 1.73m2 (60mlmin1 1.73m2) with complete baseline data.
Table 4 | CKD, inflammation, and the risk of adverse events
Cardiac outcome Stroke outcome Mortality outcome Composite outcome
Events HR (95% CI) Events HR (95% CI) Events HR (95% CI) Events HR (95% CI)
+ Inflammation
+ CKD n=446 131 1.39 (1.15, 1.68) 70 1.57 (1.22, 2.04) 242 2.01 (1.74, 2.31) 292 1.58 (1.39, 1.79)
+ Inflammation
 CKD n=3055 525 1.40 (1.26, 1.55) 254 1.56 (1.34, 1.82) 669 1.47 (1.34, 1.61) 1048 1.40 (1.30, 1.51)
 Inflammation
+ CKD n=1124 261 1.20 (1.04, 1.37) 139 1.39 (1.14, 1.69) 429 1.57 (1.41, 1.76) 549 1.28 (1.16, 1.41)
 Inflammation
 CKD n=15 361 1566 Reference 620 Reference 1719 Reference 3069 Reference
P-value (interaction) 0.12 0.05 0.13 0.13
CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio.
HR (95% CI) for adverse events in multivariable models that included the interaction term, CKD*inflammation. Percent of individuals with an event is presented below the HR.
The P-value refers to the interaction term itself, where b-coefficients were 0.18, 0.32, 0.14, and 0.12, respectively.
Multivariable models are adjusted for variables described in the caption to Table 2.
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the modified inflammation composites remained similar to
those presented (data not shown).
Finally, as albumin and WBC count are routinely obtained
in medical practice, we re-defined inflammation composite as
being in both the upper quartile of race-specific WBC count
and the lower quartile of albumin in the CHS cohort,
resulting in 472 (8.4%) of individuals defined with inflam-
mation. We then defined elevated CRP as 49.0 mg l1
(n¼ 484, 8.6%) by taking a similar percentage of individuals.
There again was significant agreement between inflammation
indicators (j-coefficient¼ 0.16; Po0.001) despite only 23%
of individuals with ‘inflammation’ having high CRP. In
multivariable models, the magnitude of risk associated with
the inflammation composite and elevated CRP was very
similar (Table 6). Notably in the CKD subgroup, the
inflammation composite, but not elevated CRP, was associated
with cardiac events in multivariable models (HRinflammation¼
1.41 (1.02, 1.96) versus HRCRP¼ 1.00 (0.71, 1.39)), although
hazards for the composite outcome were similar
(HRinflammation¼ 1.26 (1.00, 1.59) versus HRCRP¼ 1.30
(1.04, 1.63)).
DISCUSSION
In this study, we confirm the association between markers
of inflammation and mortality and cardiovascular outcomes
in a community-based population, regardless of the presence
or absence of reduced kidney function. In exploring this
relationship, we found that, although both CKD and
inflammation are associated with increased risk of adverse
events, they factors do not exhibit synergy. Additionally, we
demonstrate that, regardless of kidney function, a composite
of reduced serum albumin, elevated fibrinogen, and elevated
WBC count, and a composite of only the more common
measures (albumin and WBC count), both predict adverse
events in an elderly population to a degree similar as CRP.
Markers of inflammation have previously been evaluated
in several studies of the general population. CRP, evaluated in
a nested case–control study within a subset of Atherosclerosis
Risk in Communities Study (ARIC), was a risk factor for
coronary outcomes; however, this effect was attenuated by
accounting for other markers of inflammation, including
WBC count and fibrinogen.13 Other inflammatory markers,
including fibrinogen, were evaluated in other studies of the
Table 5 | Inflammation composite and elevated CRP in the subgroup of individuals from CHS
Event n (%) Cardiac 1222 (21.8%) Stroke 688 (12.3%) Death 1878 (33.6%) Composite 2623 (46.9%)
Univariate
Inflammation 1.48 (1.31, 1.68) 1.40 (1.18, 1.66) 1.51 (1.37, 1.67) 1.40 (1.28, 1.53)
Elevated CRP 1.44 (1.27, 1.63) 1.33 (1.12, 1.58) 1.46 (1.32, 1.62) 1.36 (1.25, 1.49)
Multivariable
Inflammation 1.28 (1.13, 1.46) 1.22 (1.03, 1.45) 1.25 (1.13, 1.38) 1.20 (1.09, 1.31)
Elevated CRP 1.29 (1.13, 1.47) 1.20 (1.01, 1.43) 1.31 (1.18, 1.45) 1.26 (1.15, 1.38)
CHS, Cardiovascular Health Study; CRP, C-reactive protein.
The variable, inflammation, refers to having two of the following three characteristics: upper quartile of fibrinogen, upper quartile of race-specific WBC count, and lower
quartile of albumin. For this comparison, elevated CRP X3.6mg l1.
Multivariable models were adjusted for age, sex, race, CKD, cardiovascular disease, diabetes, hypertension, smoking, systolic blood pressure, and non-HDL cholesterol.
Education, race, body mass index, and alcohol use were not statistically significant in composite models, and therefore were not included in these multivariable models.
Table 6 | Abbreviated inflammation composite (based only on reduced albumin and elevated WBC count) and elevated CRP in
the subgroup of individuals from CHS
Cardiac Stroke Death Composite
Entire population
Univariate
Events (%) 1222 (21.8%) 688 (12.3%) 1878 (33.6%) 2623 (46.9%)
Inflammation 1.50 (1.25, 1.80) 1.39 (1.09, 1.78) 1.62 (1.41, 1.87) 1.45 (1.28, 1.65)
Elevated CRP 1.45 (1.21, 1.73) 1.64 (1.30, 2.06) 1.56 (1.35, 1.80) 1.45 (1.28, 1.64)
Multivariable
Inflammation 1.36 (1.13, 1.63) 1.23 (0.96, 1.59) 1.34 (1.16, 1.55) 1.28 (1.12, 1.45)
Elevated CRP 1.23 (1.02, 1.48) 1.46 (1.16, 1.85) 1.34 (1.16, 1.55) 1.30 (1.15, 1.48)
CKD only
Multivariable
Events (%) 338 (27.9%) 191 (15.7%) 608 (50.1%) 749 (61.7%)
Inflammation 1.41 (1.02, 1.96) 1.41 (0.91, 2.18) 1.10 (0.84, 1.43) 1.26 (1.00, 1.59)
Elevated CRP 1.00 (0.71, 1.39) 1.57 (1.05, 2.36) 1.14 (0.89, 1.45) 1.30 (1.04, 1.63)
CHS, Cardiovascular Health Study; CKD, chronic kidney disease; CRP, C-reactive protein; WBC, white blood cell.
The variable, inflammation, refers to having both of the following: upper quartile of race-specific WBC count and lowest quartile of albumin among all individuals with CRP
levels.
Multivariable models were adjusted for age, sex, race, CKD (or eGFR in CKD only), cardiovascular disease, diabetes, hypertension, smoking, systolic blood pressure, and non-
HDL cholesterol. Education, race, body mass index, and alcohol use were not statistically significant in composite models, and therefore were not included in these
multivariable models.
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ARIC population.14 Investigators found an independent
relationship between both fibrinogen and metabolic syn-
drome with cardiac and mortality events; notably, this
relationship was additive rather than synergistic. Finally,
again within ARIC, Saito et al.1 investigated the subpopula-
tion of 1676 diabetic subjects and found that low albumin,
and high WBC count, fibrinogen, von Willebrand factor, and
factor VIII activity predicted incident coronary disease. WBC
count has also been evaluated as a coronary artery disease risk
factor. One study described an association between high WBC
count and angiographic coronary disease in the absence of a
similar association for elevated CRP.15 Further, the Baltimore
Longitudinal Study of Aging described a near linear relation-
ship between WBC count and cardiovascular events.16
Other studies have specifically focused on inflammatory
markers in CKD. Shlipak et al.17 investigated non-traditional
CVD risk factors in the CHS population and, in fully
adjusted multivariable models, found that both fibrinogen
and CRP were associated with increased absolute risk of
cardiovascular mortality only in individuals who did not
have CKD (although CRP trended to increased risk in those
with CKD). In National Health and Nutrition Examination
Survey (NHANES) III, the cross-sectional association be-
tween inflammation, marked by elevated CRP, and metabolic
syndrome was significant regardless of kidney function.18
This study expands on current knowledge by (1) using
multiple indicators together to indicate inflammation; (2)
evaluating for a unique role of inflammation in CKD as
compared with the general population; and (3) comparing
the utility of two very common and inexpensive laboratory
tests to CRP as a risk factor for adverse outcomes in
individuals with and without CKD. Notably, adding these
variables to models in the entire population or just in those
with CKD did not have a substantial effect on overall
predictive ability despite statistical significance. This pheno-
menon is expected when adding variables to multivariable
models that are already well fit.19,20
An interaction term in statistical models can test whether
the impact of a risk factor is modified by the presence of a
second risk factor. When the b-coefficient for an interaction
term between two risk factors is positive, it implies that these
two risk factors have more than additive risk. Less clear is the
interpretation of a statistically significant interaction term of
negative magnitude. In a model without collinearity, this
finding would imply that the presence of these two risk
factors in conjunction is protective versus the presence of one
of these alone. However, in a model with collinearity, the
implication is that these factors include common risk,
implying perhaps that the effects of one risk factor may be
mediated through effects of the second risk factor. The
finding that the interaction term for CKD and inflammation
had b-coefficients that were negative in magnitude for the
study outcomes with trends toward statistical significance,
suggests that CKD and inflammation in part identify
common risk and supports the finding that heightened
inflammation accompanies reduced kidney function.12
Finally, we demonstrate that two very commonly mea-
sured analytes, WBC count and albumin, have associations
with events comparable to that of CRP, regardless of kidney
function; this finding questions whether there is a significant
role for CRP in clinical risk stratification in older adults.
This study has several weaknesses. Most notably, we lack
data on proteinuria. We do not have CRP data in ARIC,
preventing overall investigation of this inflammatory marker
in comparison with more common measures like reduced
serum albumin and WBC count. Additionally, the CRP assay
used was not a high-sensitivity assay, meaning we lack the
ability to discriminate at the lowest CRP levels.
This study also has multiple strengths. We evaluate a
relatively large stage-3 CKD population with African
American representation that likely has generalizability to
the US population. Additionally, for wider applicability, we
indirectly calibrated albumin and serum creatinine to
NHANES III samples. This allows accurate assessment by
these laboratories within our study, as well as reproducibility
in other community-based populations. We also use race-
specific WBC values, as normal WBC levels can differ
dramatically by race. In general, this was not performed in
other studies examining WBC count and cardiovascular
outcomes. Further, we evaluate multiple outcomes, including
stroke, coronary disease, and mortality, to assess the overall
impact of inflammatory markers on outcomes.
In conclusion, both CKD and inflammation are associated
with increased risk of cardiovascular, stroke, and mortality
events, but do not exhibit synergy. A composite indicator of
inflammation, using data on albumin, fibrinogen, and WBC
count, as well as a more parsimonious indicator, using data
on only albumin and WBC count, is associated with adverse
events to a similar degree as CRP.
MATERIALS AND METHODS
Study design
This study is a secondary evaluation of two community-based,
longitudinal, limited-access data sets designed to evaluate CVD: the
ARIC and CHS.
Study population. Between 1987 and 1989, ARIC enrolled
15 792 participants aged 45–64 years from four communities. The
Mississippi cohort is entirely African American and comprises over
80% of the African Americans in ARIC. CHS is a population-based
study of 5201 subjects 65 years and older randomly selected from
Medicare eligibility files in four communities during 1989 and 1990.
CHS recruited an additional 687 African Americans in 1992 and
1993.21,22
Ascertainment of level of kidney function. Baseline serum
creatinine levels were assessed in 15 582 (99%) and 5716 (97%)
subjects in ARIC and CHS, respectively. Kidney function was
quantified using estimated glomerular filtration rate derived from
the four-variable Modification of Diet in Renal Disease (MDRD)
study equation.23,24 Because serum creatinine assays vary across
laboratories, we calibrated the ARIC and CHS laboratories indirectly
using NHANES III data.25,26 We defined CKD as estimated
glomerular filtration rate below 1 ml s1 1.73 m2 (60 ml min1
1.73 m2).27 Subjects with stage-5 CKD (GFR o0.25 ml min1
1.73 m2 (15 ml min1 1.73 m2)) were excluded.
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Markers of inflammation: WBC count, albumin, fibrinogen,
and CRP. WBC count was measured in citrated samples in CHS
and ARIC in local laboratories on fresh specimens. Although both
ARIC and CHS used the bromocresol green method to assess serum
albumin, results appeared discrepant by study, as mean serum
albumin was significantly higher in CHS than ARIC. Discrepancies
in albumin measurements may relate to different processing times,
non-specific interference from binding to non-albumin proteins, or
laboratory calibration differences.28,29 Therefore, we indirectly
calibrated both ARIC and CHS serum albumin levels to NHANES
III levels (also measured with a bromocresol green method) using a
regression equation that accounted for albumin, age, and sex. This
resulted in 2.3 g l1 (0.23 g per 100 ml) being added to ARIC values,
0.3 g l1 (0.03 g per 100 ml) added to values in the CHS original
cohort, and no change to values in the CHS African American
cohort. In ARIC, plasma fibrinogen was measured by the thrombin-
time titration method with reagents and calibration materials
(Fibriquik) obtained from General Diagnostics (Organon-Technika
Co., Morris Plains, NJ, USA). In CHS, fibrinogen was measured with
a BBL fibrometer (Becton Dickinson, Cockeysville, MD, USA).
Based on comparisons to NHANES III data, calibration was not
necessary for plasma fibrinogen (data not shown). CRP was
available only in CHS and was measured in plasma using an
automated assay on the BNII nephelometer (Dade Behring Inc.,
Newark, DE, USA).
Baseline covariates. These included demographics (age, sex,
race); medical history (baseline CVD, diabetes mellitus, smoking);
physical findings (systolic blood pressure, left-ventricular hypertro-
phy, body mass index, diastolic blood pressure); and laboratory
variables (total cholesterol, high-density lipoprotein cholesterol,
hemoglobin). The methods employed for collection of baseline data
by each of these studies have been described previously.21,22
Race was White or African American. Education level was
dichotomized by high school graduation. Cigarette smoking and
alcohol use were dichotomized as current users and non-users.
Diabetes was defined by insulin use, oral hypoglycemic medication
use, or fasting glucose level X7 mmol l1 (126 mg per 100 ml).
Hypertension was defined as systolic blood pressure X140 mm Hg,
diastolic X90 mm Hg, or antihypertensive medication use. Body
mass index was calculated using the formula: weight (kg)/ height2
(m). Left-ventricular hypertrophy was defined using resting 12-lead
electrocardiogram in all studies in subjects meeting voltage criteria
and having characteristic S-T segment or T-wave changes.30 Baseline
CVD included a history of both recognized and silent myocardial
infarction (MI); angina; angioplasty and coronary bypass proce-
dures; stroke; transient ischemic attack; and intermittent claudica-
tion as defined by consensus committees for the respective studies.
Baseline CVD also included a history of congestive heart failure in
CHS (not coded in ARIC). The methods employed to define CVD
outcomes are extensively described elsewhere.21,22
Exposures
Because we were interested in examining inflammation, we used the
available inflammatory markers in both CHS and ARIC, namely
serum albumin, plasma fibrinogen, and WBC count. We defined
inflammation as being in the worst quartile of any two of these
three variables (lowest albumin, highest fibrinogen, and highest
WBC count). Quartile of WBC count was race-specific, as African
Americans typically have lower WBC counts than Whites.31
Sensitivity analyses using non-race-specific WBC count were
performed.
Outcomes
The primary study outcome was a composite of MI, coronary
revascularization procedure, stroke, and all-cause mortality. MI was
defined by both clinically recognized and silent infarctions, with
ascertainment of silent MI by screening electrocardiogram. Second-
ary outcomes were cardiac events (fatal coronary heart disease,
MI, coronary revascularization), stroke, and all-cause mortality.
Committees within each study adjudicated events. Individuals were
censored at 10 years.
Study population
From an initial population of 21 680, we excluded 575 subjects
who had data missing on either age, race, sex, creatinine, or were of
non-White/non-African American race; 36 subjects with estimated
glomerular filtration rate o15 ml min1 1.73 m2; 93 subjects who
did not provide permission to release data; three subjects without
follow-up data; and 556 subjects with missing baseline CVD data.
An additional four individuals had data on fibrinogen, albumin, or
WBC count missing. Among the remaining 20 413 subjects, 1649
had CKD. Of these, 19 986 individuals in total and 1570 with CKD
had data on all baseline covariates.
Analysis and statistical methods
The goal of our analysis was to determine the relationship between
markers of inflammation and outcomes in individuals with CKD,
and compare these to data from individuals without reduced kidney
function. A secondary goal was to compare the association of the
composite of serum albumin, WBC count, and fibrinogen, as well as
a composite only including albumin and WBC count, to that seen
with CRP for adverse outcomes in individuals with CKD in the CHS
cohort.
Risk factors were explored using plots, means, and percentages.
We examined reduced albumin, elevated WBC count, and elevated
fibrinogen in univariate and multivariable proportional hazards
models. We then used the composite definition of inflammation
(worst quartile in two of three markers) and examined the HRs for
the inflammation composite and its individual components in
univariate and multivariable models. Variables a priori included in
multivariable models were known traditional cardiovascular risk
factors (age, sex, diabetes, smoking, left-ventricular hypertrophy and
systolic blood pressure, and non-high-density lipoprotein choles-
terol) as well as history of prior CVD, race, and a term for study of
origin (ARIC versus CHS). When evaluating the entire population, a
term for CKD was included in all models; in subgroup analysis
examining only individuals with CKD, estimated glomerular
filtration rate was included in models. The proportional hazards
assumption was tested by graphically exploring Schoenfeld residuals.
Multiple interaction terms were tested. Because inflammation
may influence effects of CKD on adverse outcomes, the interaction
between CKD and inflammation was tested, first in a parsimonious
model that included only terms for CKD, inflammation, and their
interaction, and then in full multivariable models.
Analyses using CRP. We defined elevated CRP (CHS only) as
comprising a similar number of individuals as the inflammation
composite. Correlation between CRP and other markers of inflam-
mation was assessed with j-statistics. We then repeated the analyses
above to evaluate the hazard associated with CRP versus the hazard
associated with the inflammation composite for adverse outcomes
in both the entire population and the subgroup with CKD. In
sensitivity analyses, we defined high CRP first as X3 mg l1 and
then as X10 mg l1, and subsequently varied the cut-off points for
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other inflammatory markers to develop an inflammation composite
with similar numbers of individuals for each of these CRP levels.
We repeated analyses using these revised definitions.
Finally, as albumin and WBC count are common and inexpen-
sive laboratory tests, we redefined inflammation as the highest
quartile of race-specific WBC count and the lowest quartile of
serum albumin, and redefined elevated CRP as comprising a similar
number of individuals as the albumin and WBC count-only
inflammation composite. We then examined models including
these variables as predictors of adverse events. All analyses were
conducted with SAS Version 9.1.
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